{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lipshultz SE"],"funding":["NICHD NIH HHS","NIAID NIH HHS","NHLBI NIH HHS","NCI NIH HHS"],"pagination":["1042-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3341148"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(10)"],"pubmed_abstract":["<h4>Purpose</h4>Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy.<h4>Patients and methods</h4>Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n = 100; 75 analyzed) or doxorubicin with dexrazoxane (n = 105; 81 analyzed). Echocardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy biomarker), and high-sensitivity C-reactive protein (hsCRP; inflammatory biomarker) were obtained before, during, and after treatment.<h4>Results</h4>cTnT levels were increased in 12% of c"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes."],"pmcid":["PMC3341148"],"funding_grant_id":["R13 HL087708","CA068484","CA127642","R01 CA127642","HL007188","HD80002","R01 HL053392","F31 HL094100","HL094100","R01 HL072705","HL053392","K30 HL004537","HL072705","HL087000","U01 AI050274","HD052104","AI50274","HD052102","R01 HL078522","P01 CA068484","R01 HL095127","U01 HD052102","U01 HD052104","HL078522","HL087708","R01 HL087000","HL004537","HL095127","HL079233","T32 HL007188"],"pubmed_authors":["Sallan SE","Neuberg DS","Schorin MA","Michon B","Lipsitz SR","Dahlberg SE","Clavell LA","Scully RE","Laverdiere C","Lipshultz SE","Miller TL","Rifai N","Colan SD","Henkel JM","Asselin BL","Athale UH","Silverman LB"],"additional_accession":[]},"is_claimable":false,"name":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.","description":"<h4>Purpose</h4>Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy.<h4>Patients and methods</h4>Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n = 100; 75 analyzed) or doxorubicin with dexrazoxane (n = 105; 81 analyzed). Echocardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy biomarker), and high-sensitivity C-reactive protein (hsCRP; inflammatory biomarker) were obtained before, during, and after treatment.<h4>Results</h4>cTnT levels were increased in 12% of c","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Apr","modification":"2025-05-29T20:05:26.003Z","creation":"2025-05-29T20:05:26.003Z"},"accession":"S-EPMC3341148","cross_references":{"pubmed":["22370326"],"doi":["10.1200/jco.2010.30.3404","10.1200/JCO.2010.30.3404"]}}